Globus strengthens position as UK's leading force in hand protection

Published: 5-Mar-2010
Personal Protection Regulatory

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

From 1 March 2010 Globus has taken over all Showabest activities in the UK and Ireland. The addition of unique chemical protection products and the world's most advanced disposable glove offer gives Globus the only product portfolio that can claim the original iconic styles that created totally new markets for their distribution partners.

Grip style gloves, Palm Fit technology, Dyneema cut protective gloves and the world's first and patented disposable nitrile glove were all created by the Showabest organisation.

Innovative sales & marketing techniques have seen Globus rise to the forefront of the hand protection sector. Its customers now look set to enjoy the benefits of an invigorated range supported by UK stock and extensive sales support infrastructure.
See more

You may also like

Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

Read more
The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway

Trending Articles

  1. IMed Group appoints Spencer Keegan as Talent Acquisition Manager IMed confirms expansion of business and implements new recruitment services for clients
  2. SGS granted approval for resumption of human ADME using carbon-14 The approval allows SGS to resume carbon-14 human ADME studies at its clinical pharmacology unit in Antwerp, reinstating a specialised capability in early-phase clinical research across Europe
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    FDA grants approval for commercial manufacturing at Rezon Bio's Warsaw-Duchnice facility Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the US Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar
  4. NJM introduces next-generation Bronco 4 pressure-sensitive labeler New system simplifies labeling for pharmaceuticals, nutraceuticals and cosmetics
  5. Moderna granted marketing authorisation for COVID-19 vaccine in Europe The product is now Moderna's third in its respiratory vaccine portfolio to be authorised in the European Union, following the approval of Spikevax and mRESVIA

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Regulatory

American Chemistry Council's statement to Trump: make chemistry in America again

The Council has released a statement ahead of the President's State of the Union Address, asking for policies that unlock domestic production and address unfair foreign practices
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Regulatory

NICE approves Opzelura cream as first UK treatment for non-segmental vitiligo

Incyte Biosciences UK has secured NICE approval for Opzelura (ruxolitinib) cream, granting eligible NHS patients with non-segmental vitiligo access to the first and only approved therapy in England shown to support facial re-pigmentation
Regulatory

CDA-AMC rejects Leqembi reimbursement despite Health Canada approval

After expressing disappointment about a separate insomnia ruling, Eisai has criticised a draft decision by Canada's drug agency not to recommend public reimbursement of Leqembi for early Alzheimer's disease
Regulatory

Shield Therapeutics’ ACCRUFeR becomes first FDA-approved oral iron for children 10+

The FDA's approval for ACCRUFeR (ferric maltol) to treat iron deficiency in children aged 10 and older makes it the first and only prescription oral iron therapy specifically approved for this pediatric population
Regulatory

Hansa Biopharma’s imlifidase BLA accepted for FDA review

The US Food and Drug Administration has accepted the company's Biologics License Application for imlifidase, a novel IgG-cleaving enzyme designed to enable HLA-incompatible kidney transplantation
Subscribe now